Stroke prevention and stroke thrombolysis: Quantifying the potential benefits of best practice therapies

Medical Journal of Australia

Volumn 190, Issue 12, 2009, Pages 678-682

  Kleinig, Timothy J ^a   Kimber, Thomas E ^a   Thompson, Philip D ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; DISABILITY; FATALITY; FEMALE; GROUPS BY AGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SMOKING; STROKE; STROKE UNIT; SYSTOLIC BLOOD PRESSURE; TERTIARY HEALTH CARE; TREATMENT OUTCOME; TREATMENT PLANNING; AUSTRALIA; COMPARATIVE STUDY; FIBRINOLYTIC THERAPY; FOLLOW UP; INCIDENCE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; AUSTRALIA; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; STROKE; SURVIVAL RATE; THROMBOLYTIC THERAPY;

EID: 68349117320     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02635.x     Document Type: Article

References (32)

1. Sturm JW, Dewey HM, Donnan GA, et al. Handicap after stroke: how does it relate to disability, perception of recovery, and stroke subtype? The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2002; 33: 762-768.
2. Thrift AG, Dewey HM, Macdonell RA, et al. Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2000; 31: 2087-2092.
3. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000; 172: 592-596.
4. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke 2006; 37: 2181-2188.
5. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
6. Cadilhac D, Hankey G, Harris D, et al on behalf of the National Stroke Foundation and the National Stroke Audit Collaborative. National stroke audit clinical report acute services. Melbourne: NSF, 2007. http://www.strokefound tion.com.au/images/stories/healthprofession als/ national%20stroke%20audit%20clinical %20report%20acute%20services.pdf (accessed May 2009).
7. Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36: 483-488.
8. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke 2007; 38: 1881-1885.
9. Chalmers J, Todd A, Chapman N, et al. International Society of Hypertension (ISH): statement on blood pressure lowering and stroke prevention. J Hypertens 2003; 21: 651-663.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
12. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
13. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006; 113: 5-14.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
15. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361: 107-116.
16. Hankey GJ. Smoking and risk of stroke. J Cardiovasc Risk 1999; 6: 207-211.
17. Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Chest 2004; 126: 1938-1945.
18. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
19. National Heart Foundation of Australia. Hypertension management guide for doctors. Canberra: NHFA, 2003.
20. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 776-785.
21. Hankey GJ, on behalf of the National Blood Pressure Advisory Committee of the National Heart Foundation. Non-valvular atrial fibrillation and stroke prevention [position statement]. Med J Aust 2001; 174: 234-239.
22. Baker RI, Coughlin PB, Gallus AS, et al; the Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.
23. Hardie K, Jamrozik K, Hankey GJ, et al. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc Dis 2005; 19: 179-185.
24. Curioni C, André C, Veras R. Weight reduction for primary prevention of stroke in adults with overweight or obesity. Cochrane Database Syst Rev 2006; (4): CD006062.
25. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke 2003; 34: 2475-2481.
26. Reynolds K, Lewis B, Nolen JD, et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 2003; 289: 579-588.
27. Marti-Fabregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1121.
28. Chitravas N, Dewey HM, Nicol MB, et al. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007; 68: 1687-1693.
29. Sturm JW, Davis SM, O'Sullivan JG, et al. The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust 2002; 176: 312-316.
30. Rother J, Alberts MJ, Touze E, et al. Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008; 25: 366-374.
31. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin 2005; 21: 1583-1594.
32. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503. (Pubitemid 47212371)